



NOTTINGHAM LIFE SCIENCE IN NUMBERS:

2 leading research universities

2 We are Pioneer Group innovation ecosystems

91,000* people employed in 14,000 Life Science and healthcare related companies

Biggest cluster of MedTech companies in the UK

91% survival rate over a 12 twelve year period of companies based at BioCity Nottingham (part of We Are Pioneer Group).

** Includes NHS workers*





Nottingham's legacy of innovation and discovery, which includes the discovery of Ibuprofen and MRI machine; is continued today with a vibrant and dynamic life science and business sector. A united community of leading research universities, pioneering life science ventures and meaningful relationships between academia, industry, government bodies and trade associations; supported by We are Pioneer Group (WAPG).

Nottingham is able to offer a dedicated business support ecosystem through organisations such as [Medilink East Midlands](#) and life science and healthcare hubs at [BioCity Nottingham](#) and [MediCity](#).


COVID 19 has caused devastation throughout the world and here in Nottingham we're proud to have been involved in [vaccine research](#) and remain committed to supporting our communities, partners and the [global effort](#) - <https://www.nottingham.ac.uk/research/covid-19/index.aspx>



KEY FIGURES IN NOTTINGHAM'S LIFE SCIENCES

We Are Pioneer Group | We are Pioneer Group create innovation ecosystems for the business of science. Integrating venture development, investment, real estate and powerful sector-specific business-focused networks, WAPG create the environments in which science and technology businesses are more likely to succeed. By creating an essential link between academia, healthcare networks and industry, WAPG have bolstered the prosperity of the city and Nottingham's position as a leader in the UK's life sciences industry; via:

- Increased tech transfer from universities
- Creation of new jobs
- Increased talent retention from the universities
- Science and innovation clusters enabling collaboration & new opportunities
- Sector specialisms in CROs, digital health, medtech and oncology
- Destination for inward investment
- Inspiring the next generation through opportunities and events for young people in Nottingham



Nottingham University Hospitals | Nottingham University Hospitals (NUH) host hundreds of clinical research studies every year, with more than 300 doctors, nurses and health professionals involved in clinical research. NUH NHS Trust includes the Nottingham Clinical Research Facility (2,000 m. sq. of NIHR accredited facilities) and the Nottingham Biomedical Research Centre, which has internationally recognised strength in Magnetic Resonance Imaging.

The Medical Technologies Innovation Facility (MTIF) | MTIF opened in 2020 at Nottingham Trent University's Clifton Campus, is a £23 million multi-disciplinary research and development facility that integrates work by scientists, engineers, clinicians and entrepreneurs to speed up medical product development.

The University of Nottingham School of Medicine | significant contributor to excellence in medical research, particularly in the areas of translational research; patient engagement; and commercial collaboration in drug and treatment development. According to the Research Excellence Framework (REF) 2014, over 80% of the School of Medicine's research was judged to be 'world leading' or 'internationally excellent'.

From focal points WAPG in Nottingham to Birmingham's newly opened Institute for Translational Medicine, the region is underpinned by a strong private sector base. Including globally significant companies such as 3M, Abbott Healthcare, Merck & Co., Parexcel, Walgreens Boots Alliance, Reckitt Benckiser, Albumedix and Quotient Clinical, as well as key manufacturers Jaguar Land Rover, Rolls Royce (Aerospace) and JCB.



RESEARCH TO RESIDENT | PIONEERING NOTTINGHAM SPINOUT BUSINESSES

The integrated approach between industry and public bodies, private investors and council support has created a powerful launchpad for promising young ventures.

Surepulse Medical | New-born wireless heartrate monitor

Surepulse Medical spun out to develop Surepulse VS, a single-use T shaped cap fitted with sensors and a display unit (which houses two wireless modules), Surepulse VS provides accurate and non-invasive vital signs monitoring of new-borns. Surepulse VS was awarded its CE mark in 2019 and has been trialled in NHS hospitals on over 300 newborns.

NuVision | Innovative therapies for ocular surface disease

NuVision are the creators of a 'first of its kind' human amniotic membrane-derived dry preserved biological matrix, Omnigen; a biological wound dressing which aids the regeneration and healing of the surface of the eye. In 2019, NuVision secured further investment of £1.4m to fund clinical trials on a new cutting-edge treatment for dry eye disease.

Azotic Technologies | Nitrogen fixation

Azotic Technologies' platform technology N-Fix® is a natural nitrogen fixing seed coating technology, providing a sustainable solution to fertiliser overuse and nitrogen pollution. The technology, which is based on a food-grade bacterium derived from sugarcane, is environmentally friendly and applies to all major crops. It provides a cost benefit to the grower through reduced fertiliser costs and improved yields. Winners of Innovator of the Year at the New Energy & Cleantech Awards, Azotic are undertaking trials in Japan, Vietnam, China and the Philippines, with N-Fix commercially available in Canada and North America.